收藏切换
The introduction and enlightenment of drug price management and the new price review framework in Canada
收藏切换
Yang-lu OU1, Hong-fei HU1, Ting ZHOU1, 2, *
Chinese Journal of New Drugs | 2026, 35(7) : 688 - 694
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(7): 688-694
The introduction and enlightenment of drug price management and the new price review framework in Canada
Full
Yang-lu OU1, Hong-fei HU1, Ting ZHOU1, 2, *
Affiliations
  • 1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China
  • 2Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China
Published: 2026-04-15 doi: 10.20251/j.cnki.1003-3734.2026.07.003
Outline
收藏切换

Drug price regulation is a common concern for governments worldwide, and Canada has accumulated extensive experience in this field. Its drug price management model is both representative and valuable for reference. The atented Medicine Prices Review Board (PMPRB), establishded by the Canadian federal government, formulates pricing guidelines and oversees the prices for patented drugs, which are then implemented by provincial governments. In parallel, several provincial governments regulate the prices of generic drugs within their jurisdictions through the pan-Canadian Pharmaceutical Alliance (pCPA) and its established tiered pricing framework. This study reviews the price review process for patented drugs in Canada, the new framework for price review, and the price management mechanisms for generic drug market entry and exit. It summarizes the practical experience of the Canadian drug price management system, aiming to provide reference for drug price management in China.

Canada  /  drug price management  /  patented drug  /  generic drug  /  Patented Medicine Prices Review Board
欧阳璐, 胡宏飞, 周挺. 加拿大药品价格管理与新价格审查框架介绍与启示. 中国新药杂志, 2026 , 35 (7) : 688 -694 . DOI: 10.20251/j.cnki.1003-3734.2026.07.003
Yang-lu OU, Hong-fei HU, Ting ZHOU. The introduction and enlightenment of drug price management and the new price review framework in Canada[J]. Chinese Journal of New Drugs, 2026 , 35 (7) : 688 -694 . DOI: 10.20251/j.cnki.1003-3734.2026.07.003
Year 2026 volume 35 Issue 7
40
8
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.07.003
  • Online Date:2026-10-26
  • Published:2026-04-15
Article Data
Affiliations
History
  • Accepted:2025-08-19
Affiliations
    1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China
    2Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing 211198, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.07.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT